Overtime was CytoMed Therapeutics’s largest revenue line in fiscal 2025, bringing in $279.66K of $324.39K (86%).
| Measurement [axis] | FY 2024 | FY 2025 |
|---|---|---|
| Overtime | $64.21K | $279.66K |
| At A Point In Time | $5.29K | $44.73K |
| Total | $69.50K | $324.39K |
CytoMed Therapeutics brought in $324.39K from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 366.7% from $69.50K in fiscal 2024. Overtime was the largest at $279.66K (86.2%), ahead of At A Point In Time at $44.73K (13.8%).
Compared with fiscal 2024, At A Point In Time grew 746.0% to $44.73K and Overtime grew 335.5% to $279.66K.
CytoMed Therapeutics (GDTC) reports its revenue by measurement [axis]. In fiscal 2025, Overtime was its largest revenue line, bringing in $279.66K (86.2% of the total), followed by At A Point In Time at $44.73K (13.8%).
Overtime was CytoMed Therapeutics' largest revenue line in fiscal 2025, bringing in $279.66K, or 86.2% of the $324.39K total across its two revenue lines.
At A Point In Time grew faster than Overtime in fiscal 2025, up 746.0% from $5.29K to $44.73K. Overtime grew 335.5% to $279.66K.
Every figure comes from CytoMed Therapeutics' annual financial filings, as reported. Each line keeps the name CytoMed Therapeutics gives it, and years follow its fiscal calendar.
CytoMed Therapeutics' revenue by measurement [axis] goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.